At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed May 29, 2026 at 08:00 ET
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting its lead program SAB-142 for type 1 diabetes. The press release contains no new clinical data, financial results, or regulatory milestones, it is a routine conference participation announcement with no material impact on the company's valuation.
- SAB BIO will present an oral presentation at ADA 2026 (June 5-8) and a poster at FOCIS 2026 (June 9-12).
- Presentations focus on SAB-142, a fully human anti-thymocyte immunoglobulin for Stage 3 type 1 diabetes.
- Topline data readout for the registrational Phase 2b SAFEGUARD study expected in 2H 2027.
- No new clinical data, financial figures, or regulatory decisions were disclosed in this press release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access